Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ISIS 304801 in hypertriglyceridemia
2014-003434-93Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2014
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing ISIS 304801 300 mg once weekly with Placebo (2 arms). Primary endpoint: Percent change in fasting triglycerides from baseline. Started Nov 2014; status: completed.
02
Drugs
volanesorsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2014-003434-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003434-93.